In anal Application No
PCT/GB 03/04388

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N9/02 C07K C07K14/195 C07K14/47 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K ocumentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) BIOSIS, EPO-Internal, MEDLINE, WPI Data, PAJ, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category ' P,X RAHMAN Q K ET AL: "Breaking the 8-12 non-responsiveness of C57BL/6 mice to the 19-23. malarial antigen EB200: The role of 34-43 carrier and adjuvant molecules. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 58, no. 4, October 2003 (2003-10), pages 395-403, XP002272656 ISSN: 0300-9475 (ISSN print) abstract page 396, column 1, paragraph 3 page 399, column 1, paragraph 1 -column 2, paragraph 1; table 2 page 401, column 1, paragraph 2 -page 402 Patent family members are listed in annex. Further documents are listed in the continuation of box C. X ΧI Special categories of cited documents: "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means document published prior to the international filing date but later than the priority date claimed In the art. "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 29/03/2004 9 March 2004 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 Mossier, B

In nal Application No
PCT/GB 03/04388

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	[a-1
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; SHENGWU HUAXUE YU SHENGWU WULI XUEBAO, May 2001 (2001-05) LI MING_FENG ET AL: "A candidate oral vaccine to Helicobacter pylori: Fusion protein of HspA and CtxB" Database accession no. prev200100290633 XP002272812 abstract	1-4,11, 12, 19-21, 34-43
-X- ·		1-4,11, 12,34-43
Y	abstract page 3, paragraph 2 -page 5, paragraph 1	5-7, 13-18, 24-26
X	WO 01 64739 A (COBRA THERAPEUTICS LTD)	12-15,49
Υ	7 September 2001 (2001-09-07) abstract	5-7, 13-18, 24-26
	page 4, line 4 - line 32 page 11, line 20 -page 12, line 29; claims 1-3	
X	WO 01 35810 A (DANA FARBER CANCER INST INC; SHERR DAVID (US); UNIV BOSTON (US); M) 25 May 2001 (2001-05-25) abstract page 9, line 14 -page 10, line 29 page 17, line 11 - line 15	12,14, 17,35-40
Х	US 5 830 464 A (SRIVASTAVA PRAMOD K) 3 November 1998 (1998-11-03)	48
Υ	abstract	9,22
X .	DJEHA A H ET AL: "EXPRESSION OF ESCHERICHIA COLI B NITROREDUCTASE IN ESTABLISHED HUMAN TUMOR XENOGRAFTS IN MICE RESULTS IN POTENT ANTITUMORAL AND BYSTANDER EFFECTS UPON SYSTEMIC ADMINISTRATION OF THE PRODRUG CB1954" CANCER GENE THERAPY, NORWALK, CT, US, vol. 7, no. 5, May 2000 (2000-05), pages 721-731, XP001015218 ISSN: 0929-1903 cited in the application	49
А	the whole document	1-48

Ir itional Application No PCT/GB 03/04388

		FC1/4B 03/04368		
C.(Continu Category °	etion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
	Oldbott of document, with indicator, whole appropriate, or the research			
Υ	BLACHERE N E ET AL: "HEAT SHOCK PROTEIN VACCINES AGAINST CANCER" JOURNAL OF IMMUNOTHERAPY, RAVEN PRESS, NEW YORK, NY, US, vol. 14, no. 4, 1993, pages 352-356, XP000973693 ISSN: 1053-8550 abstract	9,22		
A	WO 98 17799 A (WANG BIN ;UNIV PENNSYLVANIA (US); APOLLON INC (US); BOYER JEAN D () 30 April 1998 (1998-04-30) abstract page 14, line 1 -page 15, line 21 page 27, line 3 -page 28, line 21; claims 1,2,5-36			
Α	US 5 182 109 A (AIZAWA CHIKARA ET AL) 26 January 1993 (1993-01-26)			
A	XU G ET AL: "Strategies for enzyme/prodrug cancer therapy." CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES NOV 2001, vol. 7, no. 11, November 2001 (2001-11), pages 3314-3324, XP002272658 ISSN: 1078-0432			
A	GROVE J I ET AL: "VIRUS-DIRECTED ENZYME PRODRUG THERAPY USING CB1954" ANTI-CANCER DRUG DESIGN, BASINGSTOKE, GB, vol. 14, no. 6, December 1999 (1999-12), pages 461-472, XP009003925 ISSN: 0266-9536			
A .	SRIVASTAVA P K ET AL: "HEAT SHOCK PROTEIN-PEPTIDE COMPLEXES IN CANCER IMMUNOTHERAPY" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD. LONDON, GB, vol. 6, no. 5, 1994, pages 728-732, XP002037578 ISSN: 0952-7915			

national application No. PCT/GB 03/04388

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)							
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:							
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:							
Although claims 41 - 49 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.							
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:							
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).							
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)							
This International Searching Authority found multiple inventions in this international application, as follows:							
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.							
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.							
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:							
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:							
Remark on Protest							
No protest accompanied the payment of additional search fees.							

In tional Application No PCT/GB 03/04388

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9605866	A	29-02-1996	DE	4431401 A1	29-02-1996
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	••		AT	228016 T	15-12-2002
			AU	688101 B2	05-03-1998
•			AU	3253195 A	14-03-1996
			BR	9508765 A	
					11-11-1997
			CA	2198234 A1	29-02-1996
			MO	9605866 A2	29-02-1996
			DE	19580890 D2	19-06-1997
			DE	59510466 D1	02-01-2003
			DK	777499 T3	17-03-2003
			EP	0777499 A1	11-06-1997
			ES	2187568 T3	16-06-2003
			JP	2975117 B2	10-11-1999
			ĴΡ	10505339 T	26-05-1998
			PT	777499 T	31-03-2003
			US	6039941 A	21-03-2000
WO 0164739	Α	07-09-2001	AU	3755101 A	12-09-2001
			CA	2401533 A1	07-09-2001
			CN	1418224 T	14-05-2003
			EP	1268536 A1	02-01-2003
			WO	0164739 A1	07-09-2001
			JP	2004500097 T	08-01-2004
			US	2002165173 A1	07-11-2002
 WO 0135810	A	25-05-2001	CA	2390882 A1	25-05-2001
			ĒΡ	1241945 A2	25-09-2002
			WO	0135810 A2	25-05-2001
US 5830464	Α	03-11-1998	AU	742986 B2	17-01-2002
			ΑŬ	6056498 A	26-08-1998
			CA	2280945 A1	13-08-1998
•			EP	1001807 A1	24-05-2000
			JP	2001511183 T	07-08-2001
			MO	9834642 A1	13-08-1998
			US	6322790 B1	27-11-2003
WO 9817799	Α	30-04-1998	ΑU	729579 B2	01-02-2001
			ΑU	5002297 A	15-05-1998
			BR	9712852 A	16-11-1999
			CA	2269074 A1	30-04-1998
			ĔΡ	0958364 A1	24-11-1999
			JP	2001507216 T	05-06-2001
			KR	2001507210 T 2000052710 A	25-08-200
			WO_	9817799 A1	30-04-1998
US 51821 09	Α	26-01-1993	JP	2243633 A	27-09-1990
			JP	2849632 B2	20-01-1999
			CA	1335571 C	16-05-1995
			DE	3911442 A1	02-11-1989
			FR	2629717 A1	13-10-1989
			GB	2217600 A	
			KR	9603378 B1	09-03-199